Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IMOVAX Polio in Chinese Children and Infants
NCT00258843Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Primary completion
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of inactivated poliovirus vaccine in poliomyelitis (2 arms), sponsored by Sanofi. Primary endpoints: Occurrence of serious adverse reactions at 8 days and Occurrence of severe adverse reactions (injection site and systemic) at 8 days. Started Nov 2005; status: completed.
02
Drugs
inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT00258843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258843.